B-intervention	0	14	Intraoperative
I-intervention	15	24	ketorolac
O	25	27	in
O	28	32	high
O	32	33	-
O	33	37	risk
O	38	44	breast
O	45	51	cancer
O	52	60	patients
O	60	61	.

O	62	63	A
O	64	75	prospective
O	75	76	,
O	77	87	randomized
O	87	88	,
O	89	96	placebo
O	96	97	-
O	97	107	controlled
O	108	116	clinical
O	117	122	trial
O	122	123	.

O	124	133	Ketorolac
O	134	137	has
O	138	142	been
O	143	153	associated
O	154	158	with
O	159	160	a
O	161	166	lower
O	167	171	risk
O	172	174	of
O	175	185	recurrence
O	186	188	in
O	189	202	retrospective
O	203	210	studies
O	210	211	,
O	212	222	especially
O	223	225	in
O	226	234	patients
O	235	239	with
O	240	248	positive
O	249	261	inflammatory
O	262	269	markers
O	269	270	.

O	271	273	It
O	274	276	is
O	277	282	still
O	283	290	unknown
O	291	298	whether
O	299	300	a
O	301	307	single
O	308	312	dose
O	313	315	of
O	316	319	pre
O	319	320	-
O	320	330	incisional
O	331	340	ketorolac
O	341	344	can
O	345	352	prolong
O	353	363	recurrence
O	363	364	-
O	364	368	free
O	369	377	survival
O	377	378	.

O	379	382	The
O	383	386	KBC
O	387	392	trial
O	393	395	is
O	396	397	a
O	398	409	multicenter
O	409	410	,
O	411	418	placebo
O	418	419	-
O	419	429	controlled
O	429	430	,
O	431	441	randomized
O	442	447	phase
O	448	451	III
O	452	457	trial
O	458	460	in
O	461	465	high
O	465	466	-
O	466	470	risk
O	471	477	breast
O	478	484	cancer
O	485	493	patients
O	494	501	powered
O	502	505	for
O	506	508	33
O	508	509	%
O	510	519	reduction
O	520	522	in
O	523	533	recurrence
O	534	538	rate
O	539	540	(
O	540	544	from
O	545	547	60
O	548	550	to
O	551	553	40
O	553	554	%
O	554	555	)
O	555	556	.

O	557	565	Patients
O	566	574	received
O	575	578	one
O	579	583	dose
O	584	586	of
O	587	596	ketorolac
O	597	609	tromethamine
O	610	612	or
O	613	614	a
O	615	622	placebo
O	623	629	before
O	630	637	surgery
O	637	638	.

O	639	647	Eligible
O	648	656	patients
O	657	661	were
B-eligibility	662	668	breast
I-eligibility	669	675	cancer
I-eligibility	676	684	patients
I-eligibility	684	685	,
I-eligibility	686	693	planned
I-eligibility	694	697	for
I-eligibility	698	706	curative
I-eligibility	707	714	surgery
I-eligibility	714	715	,
I-eligibility	716	719	and
I-eligibility	720	724	with
I-eligibility	725	726	a
I-eligibility	727	737	Neutrophil
I-eligibility	737	738	-
I-eligibility	738	740	to
I-eligibility	740	741	-
I-eligibility	741	751	Lymphocyte
I-eligibility	752	757	Ratio
I-eligibility	757	758	â‰¥
I-eligibility	758	759	4
I-eligibility	759	760	,
I-eligibility	761	765	node
I-eligibility	765	766	-
I-eligibility	766	774	positive
I-eligibility	775	782	disease
I-eligibility	783	785	or
I-eligibility	786	787	a
I-eligibility	788	794	triple
I-eligibility	794	795	-
I-eligibility	795	803	negative
I-eligibility	804	813	phenotype
O	813	814	.

O	815	818	The
O	819	826	primary
O	827	835	endpoint
O	836	839	was
B-outcome-Measure	840	847	Disease
I-outcome-Measure	847	848	-
I-outcome-Measure	848	852	Free
I-outcome-Measure	853	861	Survival
I-outcome-Measure	862	863	(
I-outcome-Measure	863	866	DFS
I-outcome-Measure	866	867	)
I-outcome-Measure	868	870	at
I-outcome-Measure	871	874	two
I-outcome-Measure	875	880	years
O	880	881	.

O	882	891	Secondary
O	892	901	endpoints
O	902	910	included
B-outcome-Measure	911	917	safety
O	917	918	,
B-outcome-Measure	919	923	pain
I-outcome-Measure	924	934	assessment
O	935	938	and
B-outcome-Measure	939	946	overall
I-outcome-Measure	947	955	survival
O	955	956	.

O	957	964	Between
O	965	973	February
O	974	978	2013
O	979	982	and
O	983	987	July
O	988	992	2015
O	992	993	,
B-total-participants	994	997	203
O	998	1006	patients
O	1007	1011	were
O	1012	1020	assigned
O	1021	1023	to
O	1024	1033	ketorolac
O	1034	1035	(
O	1035	1036	n
O	1037	1038	=
B-intervention-participants	1039	1041	96
O	1041	1042	)
O	1043	1045	or
B-control	1046	1053	placebo
O	1054	1055	(
O	1055	1056	n
O	1057	1058	=
B-control-participants	1059	1062	107
O	1062	1063	)
O	1063	1064	.

O	1065	1073	Baseline
O	1074	1089	characteristics
O	1090	1094	were
O	1095	1102	similar
O	1103	1110	between
O	1111	1115	arms
O	1115	1116	.

O	1117	1125	Patients
O	1126	1129	had
O	1130	1131	a
O	1132	1136	mean
O	1137	1140	age
O	1141	1143	of
B-age	1144	1146	55
I-age	1146	1147	.
I-age	1147	1148	7
I-age	1149	1150	(
I-age	1150	1154	SD14
I-age	1154	1155	)
I-age	1156	1161	years
O	1161	1162	.

O	1163	1165	At
O	1166	1169	two
O	1170	1175	years
O	1175	1176	,
B-iv-bin-percent	1177	1179	83
I-iv-bin-percent	1179	1180	.
I-iv-bin-percent	1180	1181	1
I-iv-bin-percent	1181	1182	%
O	1183	1185	of
O	1186	1189	the
O	1190	1198	patients
O	1199	1203	were
B-outcome	1204	1209	alive
I-outcome	1210	1213	and
I-outcome	1214	1221	disease
I-outcome	1222	1226	free
O	1227	1229	in
O	1230	1233	the
O	1234	1243	ketorolac
O	1244	1246	vs
O	1246	1247	.
B-cv-bin-percent	1248	1250	89
I-cv-bin-percent	1250	1251	.
I-cv-bin-percent	1251	1252	7
I-cv-bin-percent	1252	1253	%
O	1254	1256	in
O	1257	1260	the
O	1261	1268	placebo
O	1269	1272	arm
O	1273	1274	(
O	1274	1276	HR
O	1276	1277	:
O	1278	1279	1
O	1279	1280	.
O	1280	1282	23
O	1282	1283	;
O	1284	1286	95
O	1286	1287	%
O	1287	1289	CI
O	1289	1290	:
O	1291	1292	0
O	1292	1293	.
O	1293	1295	65
O	1295	1296	-
O	1296	1297	2
O	1297	1298	.
O	1298	1300	31
O	1300	1301	)
O	1302	1305	and
O	1305	1306	,
O	1307	1319	respectively
O	1319	1320	,
B-iv-bin-percent	1321	1323	96
I-iv-bin-percent	1323	1324	.
I-iv-bin-percent	1324	1325	8
I-iv-bin-percent	1325	1326	%
O	1327	1329	vs
O	1329	1330	.
B-cv-bin-percent	1331	1333	98
I-cv-bin-percent	1333	1334	.
I-cv-bin-percent	1334	1335	1
I-cv-bin-percent	1335	1336	%
O	1337	1341	were
B-outcome	1342	1347	alive
O	1348	1349	(
O	1349	1351	HR
O	1351	1352	:
O	1353	1354	1
O	1354	1355	.
O	1355	1357	09
O	1357	1358	;
O	1359	1361	95
O	1361	1362	%
O	1362	1364	CI
O	1364	1365	:
O	1366	1367	0
O	1367	1368	.
O	1368	1370	34
O	1370	1371	-
O	1371	1372	3
O	1372	1373	.
O	1373	1375	51
O	1375	1376	)
O	1376	1377	.

O	1378	1379	A
O	1380	1386	single
O	1387	1401	administration
O	1402	1404	of
O	1405	1407	30
O	1408	1410	mg
O	1411	1413	of
O	1414	1423	ketorolac
O	1424	1436	tromethamine
O	1437	1443	before
O	1444	1451	surgery
O	1452	1456	does
O	1457	1460	not
O	1461	1469	increase
B-outcome	1470	1477	disease
I-outcome	1477	1478	-
I-outcome	1478	1482	free
I-outcome	1483	1491	survival
O	1492	1494	in
O	1495	1499	high
O	1500	1504	risk
O	1505	1511	breast
O	1512	1518	cancer
O	1519	1527	patients
O	1527	1528	.

B-outcome	1529	1536	Overall
I-outcome	1537	1545	survival
O	1546	1556	difference
O	1557	1564	between
O	1565	1574	ketorolac
O	1575	1587	tromethamine
O	1588	1593	group
O	1594	1597	and
O	1598	1605	placebo
O	1606	1611	group
O	1612	1615	was
O	1616	1619	not
O	1620	1633	statistically
O	1634	1645	significant
O	1645	1646	.

O	1647	1650	The
O	1651	1656	study
O	1657	1660	was
O	1661	1668	however
O	1669	1681	underpowered
O	1682	1689	because
O	1690	1692	of
O	1693	1698	lower
O	1699	1709	recurrence
O	1710	1715	rates
O	1716	1720	than
O	1721	1730	initially
O	1731	1742	anticipated
O	1742	1743	.

O	1744	1746	No
O	1747	1753	safety
O	1754	1762	concerns
O	1763	1767	were
O	1768	1776	observed
O	1776	1777	.

O	1778	1792	ClinicalTrials
O	1792	1793	.
O	1794	1797	gov
O	1798	1809	NCT01806259
O	1809	1810	.
